Ghrelin Exerts Analgesic Effects through Modulation of IL-10 and TGF-β Levels in a Rat Model of Inflammatory Pain
Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-β are anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to pe...
Saved in:
Published in: | Iranian biomedical journal Vol. 21; no. 2; pp. 114 - 119 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Iran
Pasteur Institute
01-03-2017
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-β are anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to peripheral and central inflammatory pain. In this study, the effects of i.p. injection of ghrelin on the early and the late phases of pain, as well as serum levels of IL-10 and TGF-β, as anti-inflammatory cytokines, were investigated in formalin-induced pain in male rats.
Adult male Wistar rats (n=48) were randomly divided into six groups: control, formalin+saline, ghrelin (40, 80, and 160 μg/kg), and morphine. Ghrelin was administered i.p. 30 min before inducing pain by formalin. Pain induced by intraplantar (i.pl.) injection of 50 µl formalin 5%, and pain behavior was studied for 60 min. Serum IL-10 and TGF-β levels were assessed by ELISA method.
The findings of the present study showed that ghrelin with high doses (80 and 160 μg/kg) significantly reduced pain intensity in both the early and the late phases of pain. The serum levels of cytokines, IL-10, and TGF-β1 showed a significant elevation with ghrelin at the dose of 160 μg/kg.
Ghrelin is effective in reducing the intensity of both the early and the late phases of inflammatory pain. It seems that ghrelin exerts its analgesic effects in part by increasing the serum levels of anti-inflammatory cytokines. |
---|---|
AbstractList | Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-β are anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to peripheral and central inflammatory pain. In this study, the effects of i.p. injection of ghrelin on the early and the late phases of pain, as well as serum levels of IL-10 and TGF-β, as anti-inflammatory cytokines, were investigated in formalin-induced pain in male rats.
Adult male Wistar rats (n=48) were randomly divided into six groups: control, formalin+saline, ghrelin (40, 80, and 160 μg/kg), and morphine. Ghrelin was administered i.p. 30 min before inducing pain by formalin. Pain induced by intraplantar (i.pl.) injection of 50 µl formalin 5%, and pain behavior was studied for 60 min. Serum IL-10 and TGF-β levels were assessed by ELISA method.
The findings of the present study showed that ghrelin with high doses (80 and 160 μg/kg) significantly reduced pain intensity in both the early and the late phases of pain. The serum levels of cytokines, IL-10, and TGF-β1 showed a significant elevation with ghrelin at the dose of 160 μg/kg.
Ghrelin is effective in reducing the intensity of both the early and the late phases of inflammatory pain. It seems that ghrelin exerts its analgesic effects in part by increasing the serum levels of anti-inflammatory cytokines. Background: Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-s are antiinflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to peripheral and central inflammatory pain. In this study, the effects of i.p. injection of ghrelin on the early and the late phases of pain, as well as serum levels of IL-10 and TGF-s, as anti-inflammatory cytokines, were investigated in formalin-induced pain in male rats. Methods: Adult male Wistar rats (n=48) were randomly divided into six groups: control, formalin+saline, ghrelin (40, 80, and 160 pg/kg), and morphine. Ghrelin was administered i.p. 30 min before inducing pain by formalin. Pain induced by intraplantar (i.pl.) injection of 50 pl formalin 5%, and pain behavior was studied for 60 min. Serum IL-10 and TGF-s levels were assessed by ELISA method. Results: The findings of the present study showed that ghrelin with high doses (80 and 160 pg/kg) significantly reduced pain intensity in both the early and the late phases of pain. The serum levels of cytokines, IL-10, and TGF-s1 showed a significant elevation with ghrelin at the dose of 160 pg/kg. Conclusion: Ghrelin is effective in reducing the intensity of both the early and the late phases of inflammatory pain. It seems that ghrelin exerts its analgesic effects in part by increasing the serum levels of anti-inflammatory cytokines. BACKGROUNDGhrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-β are anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to peripheral and central inflammatory pain. In this study, the effects of i.p. injection of ghrelin on the early and the late phases of pain, as well as serum levels of IL-10 and TGF-β, as anti-inflammatory cytokines, were investigated in formalin-induced pain in male rats.METHODSAdult male Wistar rats (n=48) were randomly divided into six groups: control, formalin+saline, ghrelin (40, 80, and 160 μg/kg), and morphine. Ghrelin was administered i.p. 30 min before inducing pain by formalin. Pain induced by intraplantar (i.pl.) injection of 50 µl formalin 5%, and pain behavior was studied for 60 min. Serum IL-10 and TGF-β levels were assessed by ELISA method.RESULTSThe findings of the present study showed that ghrelin with high doses (80 and 160 μg/kg) significantly reduced pain intensity in both the early and the late phases of pain. The serum levels of cytokines, IL-10, and TGF-β1 showed a significant elevation with ghrelin at the dose of 160 μg/kg.CONCLUSIONGhrelin is effective in reducing the intensity of both the early and the late phases of inflammatory pain. It seems that ghrelin exerts its analgesic effects in part by increasing the serum levels of anti-inflammatory cytokines. |
Author | Sadigh-Eteghad, Saeed Azizzadeh, Faranak Farajdokht, Fereshteh Mahmoodi, Javad Mohaddes, Gisou |
AuthorAffiliation | 1 Drug Applied Research Center of Tabriz University of Medical Sciences, Tabriz, Iran 2 Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran |
AuthorAffiliation_xml | – name: 1 Drug Applied Research Center of Tabriz University of Medical Sciences, Tabriz, Iran – name: 2 Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran |
Author_xml | – sequence: 1 givenname: Faranak surname: Azizzadeh fullname: Azizzadeh, Faranak organization: Drug Applied Research Center of Tabriz University of Medical Sciences, Tabriz, Iran – sequence: 2 givenname: Javad surname: Mahmoodi fullname: Mahmoodi, Javad organization: Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran – sequence: 3 givenname: Saeed surname: Sadigh-Eteghad fullname: Sadigh-Eteghad, Saeed organization: Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran – sequence: 4 givenname: Fereshteh surname: Farajdokht fullname: Farajdokht, Fereshteh organization: Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran – sequence: 5 givenname: Gisou surname: Mohaddes fullname: Mohaddes, Gisou organization: Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27703278$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc9O3DAQh60KVBboI7TysZek_hs7l0oILVukRUVoD9wsx5nsBjk2tRNUXqsP0mdqgC2it548sn_zaTzfMToIMQBCHykpqdZV_cU6295PTdk3dyWjJSspFe_QghGiC8347QFaUMLmWrLbI3Sc8x0hXFKl3qMjphThTOkFSqtdAt8HvPwJacz4LFi_hdw7vOw6cPPNuEtx2u7wVWwnb8c-Bhw7fLkuKME2tHizuih-_8JreACf8Uyy-MaOT3Hwz8nQeTsMdozpEV_bPpyiw876DB_25wnaXCw359-K9ffV5fnZunBc1qIAUFqxlmsJlWCqlsAU4wJ0zVvHleSdIlXr2tY2tGmok4JXTEhRd1IL0fAT9PUFOy9pgNZBGJP15j71g02PJtre_PsS-p3ZxgcjmRKKkhnweQ9I8ccEeTRDnx14bwPEKRuqldKMSS7_IzqHKlKJJ6p8iboUc07QvU5EiXk2a_ZmzWzWMGqYmc3OfZ_efue1669K_gdrH6RI |
CitedBy_id | crossref_primary_10_1016_j_brainres_2020_146851 crossref_primary_10_1093_pm_pny280 crossref_primary_10_1002_tox_22840 crossref_primary_10_1002_biof_1490 crossref_primary_10_1007_s13105_022_00943_z crossref_primary_10_3389_fnins_2023_1230428 crossref_primary_10_1038_s41598_019_51140_w crossref_primary_10_3390_ijms18020273 crossref_primary_10_1007_s00586_022_07429_y crossref_primary_10_1089_ham_2016_0132 crossref_primary_10_3390_ijms20102475 crossref_primary_10_1155_2020_1385138 crossref_primary_10_1007_s10753_020_01203_2 crossref_primary_10_2147_JEP_S249747 crossref_primary_10_1155_2017_4527980 crossref_primary_10_3389_fvets_2022_1016720 crossref_primary_10_2147_JPR_S260508 crossref_primary_10_1021_acs_jmedchem_1c02191 crossref_primary_10_1177_0333102417748563 crossref_primary_10_1016_j_clim_2022_108935 |
ContentType | Journal Article |
Copyright | Copyright: © Iranian Biomedical Journal 2017 |
Copyright_xml | – notice: Copyright: © Iranian Biomedical Journal 2017 |
CorporateAuthor | Drug Applied Research Center of Tabriz University of Medical Sciences, Tabriz, Iran Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran |
CorporateAuthor_xml | – name: Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran – name: Drug Applied Research Center of Tabriz University of Medical Sciences, Tabriz, Iran |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7QO 8FD FR3 P64 5PM |
DOI | 10.18869/acadpub.ibj.21.2.114 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | MEDLINE Engineering Research Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2008-823X |
EndPage | 119 |
ExternalDocumentID | 10_18869_acadpub_ibj_21_2_114 27703278 |
Genre | Journal Article |
GroupedDBID | --- 29J 2WC 3V. 53G 5GY 7X7 88E 8FI 8FJ 8R4 8R5 AAWTL ABUWG ACIWK ACPRK ADBBV AFKRA AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BENPR BPHCQ BVXVI CCPQU CGR CUY CVF CWDGH DIK E3Z EBD ECM EIF EMOBN EOJEC F5P FRP FYUFA GROUPED_DOAJ GX1 HMCUK HYE M1P ML~ M~E NPM OBODZ OK1 PQQKQ PROAC PSQYO Q2X RNS RPM SV3 TR2 UKHRP W2D XSB AAYXX CITATION 7X8 7QO 8FD FR3 P64 5PM |
ID | FETCH-LOGICAL-c3594-ee7872d385e642795e27234e893dc3753f706dcddab1bb1c543624549f5844b3 |
IEDL.DBID | RPM |
ISSN | 1028-852X |
IngestDate | Tue Sep 17 21:35:37 EDT 2024 Sat Aug 17 04:08:43 EDT 2024 Fri Jun 28 04:03:01 EDT 2024 Fri Aug 23 02:24:14 EDT 2024 Wed Oct 16 01:00:12 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | TGF-β Pain Ghrelin IL-10 Formalin test |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3594-ee7872d385e642795e27234e893dc3753f706dcddab1bb1c543624549f5844b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5274710/ |
PMID | 27703278 |
PQID | 1835360640 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5274710 proquest_miscellaneous_1877822535 proquest_miscellaneous_1835360640 crossref_primary_10_18869_acadpub_ibj_21_2_114 pubmed_primary_27703278 |
PublicationCentury | 2000 |
PublicationDate | 2017-03-00 2017-3-01 20170301 |
PublicationDateYYYYMMDD | 2017-03-01 |
PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-00 |
PublicationDecade | 2010 |
PublicationPlace | Iran |
PublicationPlace_xml | – name: Iran |
PublicationTitle | Iranian biomedical journal |
PublicationTitleAlternate | Iran Biomed J |
PublicationYear | 2017 |
Publisher | Pasteur Institute |
Publisher_xml | – name: Pasteur Institute |
References | 21474032 - Rev Bras Anestesiol. 2011 Mar-Apr;61(2):255-9, 260-5, 137-42 564014 - Pain. 1977 Dec;4(2):161-74 15491788 - Regul Pept. 2004 Nov 15;122(3):173-8 22125199 - Mol Neurobiol. 2012 Feb;45(1):76-86 22159099 - J Neurosci. 2011 Dec 7;31(49):17835-47 12359210 - Biochem Biophys Res Commun. 2002 Oct 4;297(4):700-13 27436480 - Neurosci Lett. 2016 Sep 6;630:30-7 1429677 - J Biol Chem. 1992 Nov 15;267(32):23301-8 17426506 - Int Anesthesiol Clin. 2007 Spring;45(2):27-37 9379845 - Brain Res Mol Brain Res. 1997 Aug;48(1):23-9 15117840 - Circulation. 2004 May 11;109(18):2221-6 15183037 - Front Neuroendocrinol. 2004 Apr;25(1):27-68 15135924 - Neurosci Lett. 2004 May 6;361(1-3):184-7 15107578 - J Pharmacol Sci. 2004 Apr;94(4):384-92 16215299 - Neurosignals. 2005;14(4):166-74 17362915 - Eur J Pharmacol. 2007 May 7;562(1-2):39-46 23500519 - Peptides. 2013 May;43:76-82 10988355 - Int J Immunopharmacol. 2000 Aug;22(8):603-14 15155307 - Anesth Analg. 2004 Jun;98(6):1566-73, table of contents 19327151 - Mol Pain. 2009 Mar 27;5:16 21565248 - Mol Cell Endocrinol. 2011 Jun 20;340(1):44-58 15006904 - Br J Pharmacol. 2004 Apr;141(7):1175-84 1472964 - Br J Pharmacol. 1992 Nov;107(3):660-4 11807165 - Annu Rev Pharmacol Toxicol. 2002;42:81-98 24113541 - Peptides. 2013 Dec;50:42-9 12651667 - Anesth Analg. 2003 Apr;96(4):1096-103, table of contents 19837031 - Cell. 2009 Oct 16;139(2):267-84 12483031 - Int Arch Allergy Immunol. 2002 Dec;129(4):263-76 22407485 - Amino Acids. 2012 Oct;43(4):1751-9 15232612 - J Clin Invest. 2004 Jul;114(1):57-66 23178578 - Exp Neurol. 2013 Feb;240:205-18 25647266 - Cytokine. 2015 Apr;72(2):121-9 18291254 - Surgery. 2008 Mar;143(3):334-42 24607724 - Peptides. 2014 May;55:103-9 16759671 - Neuropharmacology. 2006 Sep;51(3):497-505 |
References_xml | |
SSID | ssj0035177 |
Score | 2.2432444 |
Snippet | Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of... BACKGROUNDGhrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and... Background: Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 114 |
SubjectTerms | Analgesics - pharmacology Animals Disease Models, Animal Full Length Ghrelin - pharmacology Inflammation - blood Inflammation - complications Interleukin-10 - blood Male Morphine - pharmacology Nociception - drug effects Pain - blood Pain - complications Rats, Wistar Transforming Growth Factor beta - blood |
Title | Ghrelin Exerts Analgesic Effects through Modulation of IL-10 and TGF-β Levels in a Rat Model of Inflammatory Pain |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27703278 https://search.proquest.com/docview/1835360640 https://search.proquest.com/docview/1877822535 https://pubmed.ncbi.nlm.nih.gov/PMC5274710 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9tAEB4RpEpcKkpLmz6iRep1nXgfsX1ENAHEQ6jNgZu1L7epyAbFiUT_Fj-kv6mzaxsBlXro2bP2eme884135huAz1xYh4ZkqB0LRQW6PJorltOqsKyQ6DSMDcXJJ9-yy-v8yyTQ5MiuFiYm7Rs9T_zNIvHzHzG38nZhhl2e2PDq4kjGUGo07EEPsWEXojfbL5dpbLcYHCfNJbtuy3byfFwMlVEWXzOZ658Jw-gwMOUGOuAMp8tCp7XHvukvwPk8b_KRI5ruwssWQZLDZqavYMv5PXjR9JT89RpWx6gdxI5kcudW65oE1pHvDnVBGqLimrStecjF0ra9u8iyIqfnuFcS5S2ZHU_p73tyHtKJaoJ3UuSrWgdxdxMlfYVmtIjH8-RKzf0bmE0ns6MT2jZWoIbLQlDn8DNllufSYfiRFdKxjHHhELtYwzGAqbLR2BprlU61To0U6OYERpIVwhWh-T5s-6V374BYHCBThYYw0iLXSslqJJxNtXLccOb6kHQrWt429BllCDuCNspWGyVqo2RpyUKFdB8OunUv0dDD6YXybrmpcQyXfBwOHv8lkwXEI7nsw9tGVw-P7ZTch-yJFh8EAtH20ytof5Fwu7W39_898gPssAAHYu7aR9herzbuE_RquxkgjD89G8RfAYNoyH8ACOL3Ew |
link.rule.ids | 230,315,729,782,786,866,887,27933,27934,53800,53802 |
linkProvider | National Library of Medicine |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB7RIgQX3o_wXCSu69j7iO0jKklTkVQV5NCbtS-XoGZTxYkEf4sfwm9idm1XLUgcevas7dU3szOjnfkG4AMX1qEiGWpHQlGBLo8WihW0Li0rJToNY0Nz8vRrfnxafBoHmhzZ98LEon2jl4k_XyV--S3WVl6szLCvExuezA9kTKXS4R7cRntN0z5Jbw9gLrM4cDG4TlpIdto17hTFqBwqoyxuNFnq7wnD_DBw5QZC4Bx_mIVZa1e90z8h59-Vk1dc0eTBDTfxEO53sSf52D5-BLecfwx32mmUP5_A5hBxxaiTjH-4zbYhga_kzCGKpKU4bkg31IfM17ab-kXWNTma4SlLlLdkcTihv3-RWShEagi-SZEvahvE3XmU9DUq4Cpe7JMTtfRPYTEZLw6mtBvJQA2XpaDOoYEzywvpMHHJS-lYzrhwGPVYwzH1qfN0ZI21SmdaZ0YKdJACc9AaAx2h-TPY92vvXgCxuEBmClUo1aLQSsk6Fc5mWjluOHMDSHokqouWeKMKCUtAsepQrBDFimUVC73VA3jf41WhiYR7D-XdetfgGi75KFxZ_k8mD7GS5HIAz1uMLz_bK8cA8mvoXwoEiu7rTxD0SNXdgfzyxivfwd3pYj6rZkfHn1_BPRaCilgB9xr2t5udewN7jd29jQbwB-njCrY |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB7RIhAX3tDwXCSu68c-YvuI2qStSKsIcujNWu-uIajZRHEilb_FD-E3Mbu2oxYkDnD2rO3VN7Mzo535BuA9F8aiImlqhkJRgS6P5orltC4MKyQ6DW18c_LJ5-z8Ij8aeZqc3aivULSvq3nkLheRm38NtZWrhY77OrF4enYoQyqVxCtTx3twG202YX2i3h7CXKZh6KJ3nzSX7KJr3snzYRErrQxuNppX3yKGOaLny_WkwBn-NPPz1q57qD_Czt-rJ6-5o_GD_9jIQ7jfxaDkQyvyCG5Z9xjutFMpvz-B9THii9EnGV3Z9aYhnrfki0U0SUt13JBuuA85W5pu-hdZ1uR0gqctUc6Q2fGY_vxBJr4gqSH4JkU-qY0Xt5dB0tWoiItwwU-mau6ewmw8mh2e0G40A9VcFoJai4bODM-lxQQmK6RlGePCYvRjNMcUqM6SodHGqCqtqlRLgY5SYC5aY8AjKv4M9t3S2QMgBhfIVKEqJZXIK6VknQhr0kpZrjmzA4h6NMpVS8BR-sTFI1l2SJaIZMnSkvke6wG86zEr0VT8_YdydrltcA2XfOivLv8mk_mYSXI5gOctzrvP9goygOyGBuwEPFX3zScIfKDs7oB-8c8r38Ld6dG4nJyef3wJ95iPLUIh3CvY36y39jXsNWb7JtjAL0lVDTY |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ghrelin+Exerts+Analgesic+Effects+through+Modulation+of+IL-10+and+TGF-+beta+Levels+in+a+Rat+Model+of+Inflammatory+Pain&rft.jtitle=Iranian+biomedical+journal&rft.au=Azizzadeh%2C+Faranak&rft.au=Mahmoodi%2C+Javad&rft.au=Sadigh-Eteghad%2C+Saeed&rft.au=Farajdokht%2C+Fereshteh&rft.date=2017-03-01&rft.issn=1028-852X&rft.volume=21&rft.issue=2&rft.spage=114&rft.epage=114&rft_id=info:doi/10.18869%2Facadpub.ibj.21.2.114&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1028-852X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1028-852X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1028-852X&client=summon |